Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 4, 2006, Pages 802-805

  Bowker, Karen E ^a   Noel, Alan R ^a   MacGowan, Alasdair P ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

AUC MIC; S. aureus; VISA

Indexed keywords

DALBAVANCIN; GENTAMICIN; OXACILLIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; STAPHYLOCOCCUS AUREUS; STRAIN DIFFERENCE;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS AUREUS; TEICOPLANIN; VANCOMYCIN;

EID: 33748682693     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl311     Document Type: Article

References (13)

1. MacGowan AP, Bowker KE. Developments in PK/PD: Optimising efficacy and prevention of resistance. A critical review of PK/PD in in vitro models. Int. J Antimicrob Agents 2002; 19: 291-8.
2. Nix DE, Matthias KR, Ferguson EC. Effect of ertapenem protein binding on killing of bacteria. Antimicrob Agents Chemother 2004; 48: 3419-24.
3. Candiani G, Abbondi M, Borgonvi M et al. In vitro and in vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. J Antimicrob Chemother 1999; 44: 179-92.
4. Lin G, Credito K, Ednie LM et al. Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob Agents Chemother 2005; 49: 770-2.
5. Streit JM, Fritsche TR, Sader HS et al. Worldwide assessment of dalbavancin activity and spectrum against over 6000 clinical isolates. Diagn Microbiol Infect Dis 2004; 48: 137-43.
6. Dowell J, Seltzer E, Stogniew M et al. Dalbavancin dosage adjustments not required for patients with mild renal impairment. Clin Microbiol Infect 2003; 9, Suppl, 291 (Abstract p-1224).
7. Dowell J, Pu F, Seltzer E et al. Dalbavancin pharmacokinetics in subjects with mild or moderate hepatic impairment. In: Programs and Abstracts of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 2003. Abstract A-19, p. 4. American Society for Microbiology, Washington, DC, USA.
8. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically - Fifth Edition: Approved Standard M07-A6. NCCLS, Wayne, PA, USA, 2000.
9. Bauernfeind A. Questioning dosing regimens of ciprofloxacin. J Antimicrob Chemother 1993; 31: 789-98.
10. Andrews JM. Microbiological assays. In: Reeves DS, Wise R, Andrews JM. et al, eds. Clinical Antimicrobial Assays. Oxford: Oxford University Press, 1999; 35-44.
11. Andes DR, Craig WA. In vivo pharmacodynamic characterization of dalbavancin in the murine thigh infection model. In: Programs and Abstracts of the Forty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, 2004, Abstract A-1872 p. 39. American Society for Microbiology, Washington, DC, USA.
12. Flamm RK, Draghi DC, Goldstein BP et al. Time kill kinetics of dalbavancin against clinical isolates of staphylococci and streptococci. In: One hundred and fifth General Meeting of the American Society for Microbiology, Atlanta, 2005. p. 52. American Society for Microbiology, Washington, DC, USA.
13. Jabes D, Candiani G, Romano C et al. Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model. Antimicrob Agents Chemother 2004; 48: 1118-23.